Glyscend Ther­a­peu­tic­s' ear­ly da­ta show poly­mer mim­ics ben­e­fits of surgery in type 2 di­a­betes, obe­si­ty

Glyscend Ther­a­peu­tics re­leased topline da­ta for its poly­mer tar­get­ing type 2 di­a­betes and obe­si­ty to­day, with the hopes the can­di­date will have the same ef­fects …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.